Cardiff Oncology (CRDF) to Release Quarterly Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) is projected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Cardiff Oncology to post earnings of ($0.18) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $1.56 on Thursday. Cardiff Oncology has a 52 week low of $1.48 and a 52 week high of $4.99. The company’s 50 day moving average price is $2.42 and its two-hundred day moving average price is $2.28. The company has a market capitalization of $105.08 million, a P/E ratio of -1.97 and a beta of 1.33.

Hedge Funds Weigh In On Cardiff Oncology

Several large investors have recently modified their holdings of the business. Brooklyn Investment Group purchased a new position in Cardiff Oncology in the 3rd quarter valued at approximately $26,000. Engineers Gate Manager LP bought a new position in Cardiff Oncology in the 2nd quarter worth about $43,000. BNP Paribas Financial Markets grew its stake in Cardiff Oncology by 335.1% during the second quarter. BNP Paribas Financial Markets now owns 15,437 shares of the company’s stock valued at $49,000 after acquiring an additional 11,889 shares in the last quarter. Raymond James Financial Inc. grew its stake in Cardiff Oncology by 70.1% during the third quarter. Raymond James Financial Inc. now owns 23,632 shares of the company’s stock valued at $49,000 after acquiring an additional 9,740 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Cardiff Oncology by 23.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,956 shares of the company’s stock worth $69,000 after acquiring an additional 4,232 shares during the period. Hedge funds and other institutional investors own 16.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on CRDF shares. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Cardiff Oncology in a research note on Wednesday, January 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research report on Wednesday, January 21st. Finally, Noble Financial began coverage on Cardiff Oncology in a research note on Monday, January 5th. They set an “outperform” rating and a $12.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.13.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.